Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07377045 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma
A Phase 1 study of Pancreatic Adenocarcinoma Metastatic, sponsored by Oncomatryx Biopharma S.L..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
- 7
- Study locations
NCT07377045 is a Phase 1 study of Pancreatic Adenocarcinoma Metastatic that is actively recruiting participants, run by Oncomatryx Biopharma S.L.. The registered enrollment target is 69 participants, above the 45-participant average among 5 other Pancreatic Adenocarcinoma Metastatic trials with a reported enrollment target (53% higher). The trial reports 7 study locations across 2 states.
The verdict
NCT07377045, a Phase 1 study of Pancreatic Adenocarcinoma Metastatic, is actively recruiting participants, sponsored by Oncomatryx Biopharma S.L..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a Phase 1b dose escalation trial of OMTX705, an anti-fibroblast activation protein (FAP) antibody-drug conjugate (ADC), in combination with gemcitabine/nab-paclitaxel and tislelizumab in patients with advanced/metastatic pancreatic ductal adenocarcinoma (PDAC). The trial will be conducted in two parts (Part 1 and Part 2). Both parts will enroll participants with advanced PDAC that, in general, are eligible to receive gemcitabine/nab-paclitaxel. Part 1 is intended to determine the safe recommended dose of OMTX705 in combination with gemcitabine/nab-paclitaxel (1A) and in combination with gemcitabine/nab-paclitaxel+tislelizumab (1B). Both 1A and 1B will enroll in a standard 3+3 design. Only one dose level of OMTX705 will be selected for Part 2 by a Data Safety Monitoring Board (DSMB). In Part 2, 3 parallel randomized arms will be opened simultaneously with 1:1:1 randomization (N=15 each): OMTX705+gemcitabine/nab-paclitaxel (arm 2A), OMTX705+tislelizumab+gemcitabine/nab-paclitaxel (arm 2B) and gemcitabine/nab-paclitaxel (arm 2C, reference arm).
Conditions Studied
Interventions
- DRUG Nab-paclitaxel + Gemcitabine
- DRUG OMTX705
- DRUG Tislelizumab (i.v. 200mg)
Study Locations (7)
Other
- Hospital Universitario Vall d'Hebron (VHIO) - Barcelona
- Hospital Universitario Donostia - Donostia / San Sebastian
- ICO- Hospitalet Catalan Institute of Oncology - L'Hospitalet de Llobregat
- Hospital Universitario 12 Octubre - Madrid
- Clinica Universidad de Navarra (CUN) - Pamplona
- Hospital Clínico Universitario de Santiago - CHUS - Santiago de Compostela
Massachusetts
- Beth Israel Deaconess Medical Center (BIDMC) - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2025-10-28 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07377045
The ClinicalTrials.gov registry entry for NCT07377045 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 45-participant average among 5 other Pancreatic Adenocarcinoma Metastatic trials with a reported enrollment target (53% higher). The listed sponsor is Oncomatryx Biopharma S.L., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Adenocarcinoma Metastatic appearing as the primary indexed condition, and to 3 interventions - of which Nab-paclitaxel + Gemcitabine is the first listed.
NCT07377045 reports 7 study locations spanning 2 distinct geographic areas - top geographies include Other, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07377045 about?
NCT07377045 is a clinical study titled "Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma". This is a Phase 1b dose escalation trial of OMTX705, an anti-fibroblast activation protein (FAP) antibody-drug conjugate (ADC), in combination with gemcitabine/nab-paclitaxel and tislelizumab in patients with advanced/metastatic pancreatic ductal adenocarcinoma (PDAC). The trial will be conducted i...
What is the current status of trial NCT07377045?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2025-10-28. Estimated completion is 2029-03.
What conditions does trial NCT07377045 study?
This clinical trial studies the following conditions: Pancreatic Adenocarcinoma Metastatic.
What interventions are being tested in trial NCT07377045?
The interventions under investigation include: Nab-paclitaxel + Gemcitabine (DRUG), OMTX705 (DRUG), Tislelizumab (i.v. 200mg) (DRUG).
Who is sponsoring clinical trial NCT07377045?
This trial is sponsored by Oncomatryx Biopharma S.L., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07377045 being conducted?
This trial has 7 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Adenocarcinoma Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
The Seven Trial: Exploiting the Unfolded Protein Response
ACTIVE NOT RECRUITING · Phase 1
-
Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy
RECRUITING · Phase 2
-
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.